No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Tisotumab Vedotin is Effective as Second- or Third-Line Therapy for Recurrent Cervical Cancer

byAstrid BradshawandAlisha Yi

July 17, 2024

in StudyGraphics

Reading Time: 1 min read

Click here to read this study in NEJM.

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Perioperative toripalimab improves event-free survival in non-small cell lung cancer

All-oral chemotherapy regimen tolerable and efficacious for newly diagnosed acute myeloid leukemia

Chemotherapy exposure is independently associated with reduced pain severity in advanced pancreatic cancer

Image-guided assessment of coronary inflammation improves cardiac risk prediction for patients without obstructive coronary artery disease

RelatedReports

Nivolumab may be effective in platinum-resistant ovarian cancer

Surgery

Perioperative toripalimab improves event-free survival in non-small cell lung cancer

August 9, 2026

No significant increased risk of bladder cancer with pioglitazone use

Oncology

All-oral chemotherapy regimen tolerable and efficacious for newly diagnosed acute myeloid leukemia

July 23, 2026

Rectal indomethacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients

Chronic Disease

Chemotherapy exposure is independently associated with reduced pain severity in advanced pancreatic cancer

July 15, 2026

Cervical cancer screening practices less cost-effective than suggested guidelines

Oncology

Delayed CIN2 treatment does not increase cancer risk

June 22, 2026

Stroke expansion following intra-arterial therapy may explain worse outcomes

Reteplase associated with improved functional outcomes in ischemic stroke patients

#VisualAbstract: Temsirolimus Combined with VAC/VI Chemotherapy Did Not Improve Clinical Outcomes of Intermediate-Risk Rhabdomyosarcoma

Extensive lymphadenectomy may not increase patient survival with esophageal cancer

Benralizumab associated with histologic response in eosinophilic esophagitis

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result